DalsnaFinance

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Markets GlobeNewswire By GlobeNewswire 16 Jun 2026 12:30 1 min read
Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies

Read the full story on GlobeNewswire → Opens the original article on www.globenewswire.com

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.